Arcturus Therapeutics Holdings Inc(ARCT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -3.31 | Insider Own | 8.36% | Shs Outstand | 28.4M | Perf Week | 13.23% |
| Market Cap | 0.35B | Forward P/E | - | EPS next Y | -8.55% | Insider Trans | - | Shs Float | 26.1M | Perf Month | -11.25% |
| Enterprise Value | 0.18B | PEG | - | EPS next Q | -0.69 | Inst Own | 82.17% | Short Float | 20.96% | Perf Quarter | 110.94% |
| Income | -0.09B | P/S | 18.45 | EPS this Y | -42.71% | Inst Trans | -3.74% | Short Ratio | 5.71 | Perf Half Y | 40.95% |
| Sales | 0.02B | P/B | 2.01 | EPS next 5Y | -13.65% | ROA | -34.96% | Short Interest | 5.46M | Perf YTD | 98.21% |
| Book/sh | 6.04 | P/C | 1.8 | EPS past 3/5Y | - 7.53% | ROE | -46.31% | 52W High | -32.35% ($17.96) | Perf Year | 28.71% |
| Cash/sh | 6.74 | P/FCF | - | Sales past 3/5Y | -31.15% 47.77% | ROIC | -48.89% | 52W Low | 120.91% ($5.50) | Perf 3Y | -34% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -49.04% | Gross Margin | 85.37% | Volatility(W/M) | 9.69% 9.29% | Perf 5Y | -72.97% |
| Dividend TTM | - | EV/Sales | 9.44 | Sales Y/Y TTM | -82.95% | Oper. Margin | -563.29% | ATR (14) | 1.06 | Perf 10Y | -9.6% |
| Dividend Ex-Date | - | Quick Ratio | 5.88 | EPS Q/Q | -147.28% | Profit Margin | -498.16% | RSI (14) | 50.95 | Recom | 1.31 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.88 | Sales Q/Q | -96.41% | SMA20 | 3.04% ($11.79) | Beta | 2.59 | Target Price | $23.8 |
| Payout | - | Debt/Eq | 0.13 | Earnings | 2026/11/5 | SMA50 | -10.73% ($13.61) | Rel Volume | 0.5 | Prev Close | $12.07 |
| Employees | 111 | LT Debt/Eq | 0.11 | EPS/Sales Surpr. | 15.7% -4.78% | SMA200 | 35.23% ($8.98) | Avg Volume(3M) | 0.96M | Price | $12.15 |
| IPO | 2013/5/22 | Option/Short | Yes/Yes | Trades | 5201 | Volume | 474,795 | Change | 0.66% |
🧬 Arcturus Therapeutics (ARCT) is a U.S. biotech company that develops therapeutics for rare diseases and infectious disease vaccines based on mRNA medicines and lipid nanoparticle delivery technology. The company holds an inhaled mRNA therapeutic candidate for cystic fibrosis along with a pipeline targeting liver metabolic diseases and mRNA vaccines, and is focused on developing clinical-stage new drugs.
Over the past 1 year, roughly in the middle
32% below its 1-year high.
Traded less than usual. That is 50% of its average volume.
Next earnings report: November 5
6 days to go.
ARCT has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -42.7% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,845. Peers typically go for $1,217. It is about in line with its own 1-year average.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -73.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
21.0% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #255 of 594 in the industry
Based on market cap of $345M.
GALT#251 Galectin Therapeutics Inc $355M PER - 
CTNM#252 Contineum Therapeutics Inc $351M PER - 
SRZN#253 Surrozen Inc $346M PER - 
AVIR#254 Atea Pharmaceuticals Inc $346M PER - ARCT#255 Arcturus Therapeutics Holdings Inc $345M PER - 
FAQ
What kind of company is ARCT?
ARCT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ARCT?
The market cap of ARCT is approximately $345M, ranking 3,507 within its sector.
What is the 52-week high and low for ARCT?
ARCT has recorded a 52-week high of $17.96 and a low of $5.50.
